FDA Investigates Pediatric Death Linked to Takeda's Adzynma Therapy

The U.S. Food and Drug Administration (FDA) is currently investigating the death of a pediatric patient who developed harmful antibodies after receiving Takeda Pharmaceuticals' enzyme replacement therapy, Adzynma, for congenital thrombotic thrombocytopenic purpura (cTTP). This investigation follows reports of adverse events, including the death, which occurred approximately 10 months after the patient began treatment.

BioSpaceReutersUS FDA investigates Takeda’s blood disorder drug after pediatric death

Adzynma was approved by the FDA in 2023 as the first therapy for cTTP, a rare inherited blood disorder characterized by the formation of blood clots in small vessels, potentially leading to serious complications such as strokes and organ damage. The therapy works by replacing the missing ADAMTS13 protein, which is essential for normal blood clotting. The condition affects fewer than 1 in 1,000 people and typically manifests in infancy or early childhood.

US FDA investigates Takeda’s blood disorder drug after pediatric death

The patient in question had a history of severe allergic reactions to fresh frozen plasma, a traditional treatment for cTTP. Following treatment with Adzynma, the child developed progressive neurological symptoms and produced neutralizing antibodies against the ADAMTS13 enzyme. The FDA noted that current testing methods cannot distinguish whether these antibodies are produced in response to the enzyme replacement therapy or the body's own protein.

BioSpaceReutersUS FDA investigates Takeda’s blood disorder drug after pediatric death

Takeda Pharmaceuticals acknowledged the incident, stating, "We reported this event to the U.S. Food and Drug Administration and have been providing them with updates since we became aware in July." The company conducted an assessment and concluded that there was no confirmed causal relationship between the use of Adzynma and the patient's death. The FDA has received multiple postmarketing reports of patients developing similar antibodies after treatment, which were not observed during clinical trials.

ReutersUS FDA investigates Takeda’s blood disorder drug after pediatric deathBioSpace

Critics have raised concerns regarding the safety of Adzynma, particularly in light of the reported death and the emergence of neutralizing antibodies. The FDA's investigation highlights the potential risks associated with the therapy, prompting calls for more stringent monitoring and clearer warnings in the prescribing information.

Reuters

While the FDA's investigation indicates a potential link between Adzynma and the patient's death, Takeda maintains that no causal relationship has been confirmed. Additionally, the FDA's reports of antibody development were noted only in postmarketing settings, raising questions about the adequacy of pre-approval clinical trials in identifying such risks.

Reuters

The FDA's ongoing investigation may lead to further regulatory actions regarding Adzynma, including updates to prescribing information to better inform healthcare providers and patients about the risks of developing neutralizing antibodies. The outcome of this investigation will be closely monitored by both the medical community and patients affected by cTTP.

Reuters